Methodology

All entries for: Oncology

April 6, 2026

BioNTech

Layoffs

Arnedo, La Rioj
51-200 employees

BioNTech is closing a Singapore production plant less than four years after buying the site from Novartis to supply mRNA vaccines and therapies in the Asia-Pacific region. Last week, the Germany-based company told The Straits Times that the planned Singapore site will close by February 2027. BioNTech employs 85 people at the plant.

The company, which framed the shuttering as part of efforts to align capacity with its pipeline and long-term strategic direction, also had layoffs last year. BioNTech let go of 63 employees in August in connection with closing its cell therapy facility in Gaithersburg, Maryland. Around the same time, news broke that it would lay off 90 employees across its U.S. footprint, including 32 people at its Gaithersburg office and lab space, effective in September 2025, and 58 in Cambridge, Massachusetts.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
April 1, 2026

Adagene Inc.

Neutral Outlook

Suzhou Industrial Park, Jiangsu Province
201-500 employees

On August 16, 2022, the former President Biden signed into law the Inflation Reduction Act that includes a provision that is intended to lower certain prescription drug costs under Medicare.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
April 1, 2026

Genenta Science S.p.A.

Neutral Outlook

Milan, Lombardy
51-200 employees

Thus, while it is unclear how the IRA will be fully implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
April 1, 2026

Innate Pharma SA

Neutral Outlook

Marseille
201-500 employees

Provisions of the IRA are subject to legal challenges, and the full impact of the IRA on the pharmaceutical industry remains uncertain.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
March 31, 2026

Neonc Technologies Holdings, Inc/CA

Neutral Outlook

Calabasas, CA
1-50 employees

In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.

Disease Area: Neurological Diseases, Oncology
Drug Type: Small Molecule
Source
Source
March 31, 2026

OS Therapies Inc

Neutral Outlook

Grasonville, MD
1-50 employees

Healthcare reform legislation also influences coverage, pricing and reimbursement for biopharmaceutical products. In the United States, statutes such as the Affordable Care Act and the Inflation Reduction Act, as well as other federal and state programs, establish requirements for Medicaid and Medicare drug rebates, coverage determinations, pricing transparency and other programmatic matters.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
March 31, 2026

Kairos Pharma, LTD

Neutral Outlook

Los Angeles, CA
1-50 employees

In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.

Disease Area: Oncology
Drug Type: Small Molecule
Source
Source
March 31, 2026

OSR Holdings, Inc

Negative Outlook

Bellevue, WA
1-50 employees

The Affordable Care Act and the Inflation Reduction Act, as well as other ongoing healthcare legislative and regulatory reform measures, may have a material adverse effect on our business and results of operations.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
March 31, 2026

MiNK Therapeutics, Inc.

Neutral Outlook

New York, NY
1-50 employees

The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant.

Disease Area: Oncology
Drug Type: Small Molecule
Source
Source
March 31, 2026

Nanobiotoix S.A.

Negative Outlook

Paris, France
51-200 employees

Additionally, in the United States, the Inflation Reduction Act of 2022 (IRA), enacted on August 16, 2022, includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. We cannot predict the ultimate content, timing or effect of any changes to the ACA, the IRA or other federal and state reform efforts, and there can be no assurance that any such health care reforms will not adversely affect our future business and financial results.

Disease Area: Oncology
Drug Type: Biologic
Source
Source
Scroll to Top